NCT05896774View on ClinicalTrials.gov

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

November 6, 2024

Study Completion Date

November 6, 2024

Conditions
Non-Hodgkin LymphomaMultiple Myeloma
Interventions
DRUG

Maplirpacept

Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.

Trial Locations (5)

100142

Beijing Cancer Hospital, Beijing

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

Sir Run Run Shaw Hospital, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

510080

Guangdong Provincial People's Hospital, Guangzhou

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05896774 - A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China | Biotech Hunter | Biotech Hunter